This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Trassard, M. Articles by Coindre, J.-M. Search for Related Content PubMed PubMed Citation Articles by Trassard, M. Articles by Coindre, J.-M. Social Bookmarking                            What's this?

Prognostic Factors in Localized Primary Synovial Sarcoma: A Multicenter Study of 128 Adult Patients

From the French Federation of Cancer Centers Sarcoma Group, Paris, France.

Address reprint requests to Martine Trassard, Laboratoire d’Anatomie et Cytologie Pathologiques, Centre René-Huguenin (Directeur: Pr J. Rouëssé), 35 rue Dailly, 92210 Saint-Cloud, France; email trassardmcrh{at}yahoo.com

PURPOSE: To identify most significant and therapeutically relevant prognostic factors in adults with localized primary synovial sarcomas (SS) and to confirm the usefulness of the French Federation of Cancer Centers (FNCLCC) grading system, the prognostic impact of which has been already proven in soft tissue sarcomas.

PATIENTS AND METHODS: Data on 128 patients with nonmetastatic SS collected from a cooperative database by the FNCLCC Sarcoma Group between 1980 and 1994 were studied retrospectively. Immunohistochemistry was performed at diagnosis in 77 cases (61%). The tumors were classified as biphasic (n = 45), monophasic fibrous (n = 72), and poorly differentiated (n = 10) subtypes. Histologic grade was determined according to the FNCLCC method, and vascular invasion was assessed in every case.

RESULTS: The 5-year disease-specific survival (DSS) rate for this series of patients with localized SS was 62.9% (± 9.6% [SD]) with a median follow-up time of 37 months (range, 8 to 141 months). In multivariate analysis, the adverse risk factors associated with decreased DSS were International Union Against Cancer/American Joint Committee on Cancer stage III/IVA disease, male sex, and truncal tumor locations. For metastasis-free survival (MFS), disease stage III/IVA, tumor necrosis, and monophasic subtypes were the major factors associated with a less favorable prognosis. Separately, when not using disease stage, tumor necrosis, and mitotic activity, histologic grade became the most significant prognostic factor for both DSS and MFS. In addition, larger tumors and older patients become associated with a significantly worse prognosis. Independent adverse risk factors for local recurrence–free survival included histologic grade 3 and truncal tumor location.

CONCLUSION: These data confirm that not all SS present the same severe outcome. High-risk patients identified on the basis of these parameters may qualify for an aggressive treatment approach.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Italiano, N. Penel, Y.-M. Robin, B. Bui, A. Le Cesne, S. Piperno-Neumann, M. Tubiana-Hulin, E. Bompas, C. Chevreau, N. Isambert, et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group Ann. Onc., March 1, 2009; 20(3): 425 - 430. [Abstract] [Full Text] [PDF]

				R. J. Canter, L.-X. Qin, R. G. Maki, M. F. Brennan, M. Ladanyi, and S. Singer A Synovial Sarcoma-Specific Preoperative Nomogram Supports a Survival Benefit to Ifosfamide-Based Chemotherapy and Improves Risk Stratification for Patients Clin. Cancer Res., December 15, 2008; 14(24): 8191 - 8197. [Abstract] [Full Text] [PDF]

				I. Ray-Coquard, A. Le Cesne, J. S. Whelan, P. Schoffski, B. N. Bui, J. Verweij, S. Marreaud, M. van Glabbeke, P. Hogendoorn, and J.-Y. Blay A Phase II Study of Gefitinib for Patients with Advanced HER-1 Expressing Synovial Sarcoma Refractory to Doxorubicin-Containing Regimens Oncologist, April 1, 2008; 13(4): 467 - 473. [Abstract] [Full Text] [PDF]

				M. D. Murphey, M. S. Gibson, B. T. Jennings, A. M. Crespo-Rodriguez, J. Fanburg-Smith, and D. A. Gajewski From the Archives of the AFIP: Imaging of Synovial Sarcoma with Radiologic-Pathologic Correlation RadioGraphics, September 1, 2006; 26(5): 1543 - 1565. [Abstract] [Full Text] [PDF]

				E. L. Spurrell, C. Fisher, J. M. Thomas, and I. R. Judson Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital Ann. Onc., March 1, 2005; 16(3): 437 - 444. [Abstract] [Full Text] [PDF]

				L. Guillou, J. Benhattar, F. Bonichon, G. Gallagher, P. Terrier, E. Stauffer, N. de Saint Aubain Somerhausen, J.-J. Michels, G. Jundt, D. R. Vince, et al. Histologic Grade, But Not SYT-SSX Fusion Type, Is an Important Prognostic Factor in Patients With Synovial Sarcoma: A Multicenter, Retrospective Analysis J. Clin. Oncol., October 15, 2004; 22(20): 4040 - 4050. [Abstract] [Full Text] [PDF]

				S. Dennison, E. Weppler, and G. Giacoppe Primary Pulmonary Synovial Sarcoma: A Case Report and Review of Current Diagnostic and Therapeutic Standards Oncologist, June 1, 2004; 9(3): 339 - 342. [Abstract] [Full Text] [PDF]

				M. F. Okcu, M. Munsell, J. Treuner, A. Mattke, A. Pappo, A. Cain, A. Ferrari, M. Casanova, A. Ozkan, and B. Raney Synovial Sarcoma of Childhood and Adolescence: A Multicenter, Multivariate Analysis of Outcome J. Clin. Oncol., April 15, 2003; 21(8): 1602 - 1611. [Abstract] [Full Text] [PDF]

				S. V. Allander, P. B. Illei, Y. Chen, C. R. Antonescu, M. Bittner, M. Ladanyi, and P. S. Meltzer Expression Profiling of Synovial Sarcoma by cDNA Microarrays : Association of ERBB2, IGFBP2, and ELF3 with Epithelial Differentiation Am. J. Pathol., November 1, 2002; 161(5): 1587 - 1595. [Abstract] [Full Text] [PDF]

				M. Ladanyi, C. R. Antonescu, D. H. Leung, J. M. Woodruff, A. Kawai, J. H. Healey, M. F. Brennan, J. A. Bridge, J. R. Neff, F. G. Barr, et al. Impact of SYT-SSX Fusion Type on the Clinical Behavior of Synovial Sarcoma: A Multi-Institutional Retrospective Study of 243 Patients Cancer Res., January 1, 2002; 62(1): 135 - 140. [Abstract] [Full Text] [PDF]